In CAD patients with impaired kidney function, elevated endothelin-1 increased MACE risk (adjusted SHR 1.627), especially with diabetes (adjusted SHR 2.192).
Does elevated endothelin-1 predict major adverse cardiovascular events in coronary artery disease patients with impaired kidney function?
Elevated plasma endothelin-1 is a significant predictor of major adverse cardiovascular events in patients with coronary artery disease and impaired kidney function, particularly those with concurrent diabetes.
Absolute Event Rate: 0% vs 0%
Abstract Objective This study aimed to explore the association between endothelin-1 (ET-1) and major adverse cardiovascular events (MACE) in CAD patients with impaired kidney function with a focus on the influence of diabetes status. Methods A prospective cohort involved 1,344 CAD patients with impaired kidney function. The primary outcome was MACE, including cardiovascular mortality, nonfatal myocardial infarction, unplanned revascularization, and stroke. Statistical analyses included Cox regression, competing risks analysis (competing for non-cardiovascular death), and restricted cubic spline analysis to assess the relationships between ET-1 and MACE. Results ET-1 levels were substantially correlated with a higher risk of MACE (adjusted subdistribution hazard ratios SHR 1.627, 95% confidence interval CI 1.119-2.365). Notably, the risk of MACE was significantly higher in patients with diabetes and high ET-1 compared to reference (adjusted SHR 2.192; 95% CI 1.262-3.804). Non-linear relationships between ET-1 levels and MACE were observed, and subgroup analyses confirmed the robustness of the findings in acute coronary syndrome patients. Conclusion In CAD patients with impaired kidney function, elevated plasma ET-1 levels are related to a higher risk of MACE, particularly in those with diabetes. ET-1 might be a useful biomarker for therapeutic targeting and risk assessment in this high-risk group.
Ye et al. (Sat,) reported a other. In CAD patients with impaired kidney function, elevated endothelin-1 increased MACE risk (adjusted SHR 1.627), especially with diabetes (adjusted SHR 2.192).